BioMed Research International / 2018 / Article / Tab 2

Review Article

Optimum Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation and Undergoing Percutaneous Coronary Intervention

Table 2

Outcomes with dual therapy compared with triple therapy after PCI.

Study/authorMACE (%)
Mortality (%)
Stent thrombosis (%) Total bleeding (%) Major bleeding (%)

RE-DUAL PCI [31]NR4.9/5.6
4.6/3.9
0.8/1.5 [0.15]
0.9/0.9 [0.98]
42.9/27.1 [<0.001]
41.4/33.3 [<0.001]
9.2/5.0 [<0.001]
8.4/5.6 [0.02]
De Vecchis et al. [33]27.1/12.9 [0.32]8.3/0 [0.26]2/0 [0.59]16.7/19.4 [0.90]8.3/6.5 [0.89]
PIONEER [12]6.0/6.5 [0.75]1.9/2.4 [0.52]0.7/0.8 [0.79]26.7/16.8 [<0.01]3.3/2.1 [0.23]
ORBIT-AF [34]NR4.1/5.4 [0.57]NRNR5.68/5.85 [0.66]
AFCAS [24]22/18 [0.72]11/7 [0.54]1/3 [0.60]18/16 [0.66]10/7 [0.43]
WARSTENT [25]16/15 [0.98]5/0 [0.45]1/0 [0.76]11/5 [0.34]4/5 [0.84]
Braun et al. [35]NR3.2/3.8 [NS]0/0 [NS]NR7/7.5 [NS]
Lamberts et al. [36]NR8.9/7.1 [NS]NR14.3/10.9 [NS]0.9/0.5 [NS]
WOEST [9]NR6.3/3.5 [0.03]3.2/1.4 [0.17]44.4/19.4 [<0.01]5.6/3.2 [0.16]
Rubboli et al. [37]32/24.6 [0.19]9.9/10.2 [0.78]2.7/2.0 [0.77]NR5.0/2.6 [0.32]
Persson et al. [38]NR3.0/4.2 [0.43]NR4.7/1.3 [0.02]2.7/0.3 [0.03]
Gao et al. [39]8.8/14.9 [0.01]4.4/5.8 [0.17]0.7/1.7 [0.73]11.8/7.4 [0.038]2.9/2.5 [0.73]
MUSICA [40]23.7/26.1 [0.001]6.8/10.9 [0.06]4.0/8.7 [0.04]15.5/13 [0.02]4.3/6.5 [0.29]
Sørensen et al. [41]NR[NS]NR3.2/1.6 [NS]NR
GRACE [26]NR5.1/6.5 [0.47]NRNR5.9/4.6 [0.46]
Karjalainen et al. [42]21.9/11 [0.003]8.7/1.8 [0.003]4.1/1.3 [0.09]NR8.2/2.6 [0.01]

NR = not reported; NS = statistically nonsignificant; number preceding “/” denotes TT (triple therapy) and number proceeding “/” denotes DT (dual therapy), TT/DT; for RE-DUAL PCI: = Therapy with Dabigatran 110 mg BID; = Therapy with Dabigatran 150 mg BID.